Literature DB >> 7499270

The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A.

J O Kvassman1, D A Lawrence, J D Shore.   

Abstract

The serpin plasminogen activator inhibitor-1 (PAI-1) spontaneously adopts an inactive or latent conformation by inserting the N-terminal part of the reactive center loop as strand 4 into the major beta-sheet (sheet A). To examine factors that may regulate reactive loop insertion in PAI-1, we determined the inactivation rate of the inhibitor in the pH range 4.5-13. Below pH 9, inactivation led primarily to latent PAI-1, and one predominant effect of pH on the corresponding rate constant could be observed. Protonation of a group exhibiting a pKa of 7.6 (25 degrees C, ionic strength = 0.15 M) reduced the rate of formation of latent PAI-1 by a factor of 35, from 0.17 h-1 at pH 9 to about 0.005 h-1 below pH 6. The ionization with a pKa 7.6 was found to have no effect on the rate by which PAI-1 inhibits trypsin and is therefore unlikely to change the flexibility of the loop or the orientation of the reactive center. The peptides Ac-TEASSSTA and Ac-TVASSSTA (cf. P14-P7 in the reactive loop of PAI-1) formed stable complexes with PAI-1 and converted the inhibitor to a substrate for tissue type plasminogen activator. We found that peptide binding and formation of latent PAI-1 are mutually exclusive events, similarly affected by the pKa 7.6 ionization. This is direct evidence that external peptides can substitute for strand 4 in beta-sheet A of PAI-1 and that the pKa 7.6 ionization regulates insertion of complementary, internal or external, strands into this position. A model that accounts for the observed pH effects is presented, and the identity of the ionizing group is discussed based on the structure of latent PAI-1. The group is tentatively identified as His-143 in helix F, located on top of sheet A.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499270     DOI: 10.1074/jbc.270.46.27942

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Jeffrey I Weitz; John W Eikelboom; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  New anticoagulant drugs.

Authors:  J I Weitz
Journal:  J Thromb Thrombolysis       Date:  2001-09       Impact factor: 2.300

3.  Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.

Authors:  Valentina De Lorenzi; Gian Maria Sarra Ferraris; Jeppe B Madsen; Michela Lupia; Peter A Andreasen; Nicolai Sidenius
Journal:  EMBO Rep       Date:  2016-05-17       Impact factor: 8.807

4.  The conversion of active to latent plasminogen activator inhibitor-1 is an energetically silent event.

Authors:  Christian Boudier; Ann Gils; Paul J Declerck; Joseph G Bieth
Journal:  Biophys J       Date:  2005-01-14       Impact factor: 4.033

5.  Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.

Authors:  Zhonghui Lin; Longguang Jiang; Cai Yuan; Jan K Jensen; Xu Zhang; Zhipu Luo; Barbara C Furie; Bruce Furie; Peter A Andreasen; Mingdong Huang
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

6.  Proteolytic regulation of epithelial sodium channels by urokinase plasminogen activator: cutting edge and cleavage sites.

Authors:  Hong-Long Ji; Runzhen Zhao; Andrey A Komissarov; Yongchang Chang; Yongfeng Liu; Michael A Matthay
Journal:  J Biol Chem       Date:  2015-01-02       Impact factor: 5.157

7.  Loop variants of the serpin thyroxine-binding globulin: implications for hormone release upon limited proteolysis.

Authors:  Helmut Grasberger; Henriette M B Golcher; Anja Fingerhut; Onno E Janssen
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

8.  Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.

Authors:  Shih-Hon Li; Natalia V Gorlatova; Daniel A Lawrence; Bradford S Schwartz
Journal:  J Biol Chem       Date:  2008-04-24       Impact factor: 5.157

Review 9.  Functional stability of plasminogen activator inhibitor-1.

Authors:  Songul Yasar Yildiz; Pinar Kuru; Ebru Toksoy Oner; Mehmet Agirbasli
Journal:  ScientificWorldJournal       Date:  2014-10-15

Review 10.  Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Front Cardiovasc Med       Date:  2020-12-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.